The future of phosphate binders: a perspective on novel therapeutics

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.962652PMID 25243756
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Semaphorin 3A

  2014cited by this paper
• [A brief update on FGF23 for the clinical nephrologist].

  2014cited by this paper
• Optimal phosphate control: still an unmet need in chronic kidney disease patients

  2014cited by this paper
• Clinical Effects of the New Phosphorus Binder, Bixalomer in Hemodialysis Patients Switched From Sevelamer Hydrochloride

  2014cited by this paper
• Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein

  2014cited by this paper
• A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

  2014cited by this paper
• Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease

  2014cited by this paper
• Treatment of Hyperphosphatemia With Bixalomer in Japanese Patients on Long‐Term Hemodialysis With Gastrointestinal Symptoms

  2014cited by this paper
• Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?

  2014influential reference
• Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

  2014cited by this paper
• Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles

  2014cited by this paper
• FGF23 and Klotho in chronic kidney disease

  2013cited by this paper
• Effect of Salivary Phosphate-Binding Chewing Gum on Serum Phosphate in Chronic Kidney Disease

  2013cited by this paper
• Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis

  2013cited by this paper
• FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

  2012cited by this paper
• Effects of phosphate binders in moderate CKD.

  2012cited by this paper
• Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects

  2012cited by this paper
• Salivary glands: a new player in phosphorus metabolism.

  2011cited by this paper
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

  2009cited by this paper
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

  2009cited by this paper
• Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

  2009cited by this paper
• Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

  2006cited by this paper
• Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.

  2006cited by this paper
• Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

  2006influential reference
• Osteoprotegerin and Bone Mineral Density in Hemodiafiltration Patients

  2005cited by this paper
• Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

  2005cited by this paper

• Frailty transitions and risk of chronic kidney disease: insights from the China Health and Retirement Longitudinal Study

  2025cites this paper
• Hypercalcemia: A Practice Overview of its Diagnosis and Causes

  2025cites this paper
• Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor

  2024cites this paper
• Impact of Serum Phosphate on Hemoglobin Level: A Longitudinal Analysis on a Large Cohort of Dialysis Patients

  2024influential citation
• Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions

  2023cites this paper
• Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure

  2023cites this paper
• A systematic review and meta-analysis of efficacy and safety of Calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

  2022cites this paper
• The Role of Chronic Kidney Disease in Ectopic Calcification

  2020cites this paper
• Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

  2020cites this paper
• Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor‐23

  2020cites this paper
• Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

  2020cites this paper
• The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism

  2019cites this paper
• Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study

  2018cites this paper
• Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Population‐Based Analysis

  2018cites this paper
• The Myth of Water and Salt: From Aquaretics to Tenapanor.

  2017cites this paper
• PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure

  2017cites this paper
• Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

  2016cites this paper
• Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

  2016cites this paper
• Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

  2016cites this paper
• Semaphorin 3A serum levels are influenced by haemodialysis: What clinical significance?

  2015cites this paper
• Bone enumerates as a new endocrine organ interacted in chronic kidney disease and mineral and bone disorders

  2014cites this paper